Correction to: Clinical Drug Investigation https://doi.org/10.1007/s40261-019-00862-w
The Editor-in-Chief of Clinical Drug Investigation has become aware that this article [1] contains a number of errors and inconsistencies. In addition, concerns have also been raised regarding the study design and statistical analysis. These concerns are being investigated and an update will be provided once a resolution has been reached. Until then the conclusions of the study should be interpreted with caution.
Gideon Koren and Daniella Gilboa did not agree with this notice; Rachel Katz was informed of the intention to place this notice but did not reply to correspondence regarding this.
Reference
Koren G, Gilboa D, Katz R. Fetal safety of dydrogesterone exposure in the first trimester of pregnancy. Clin Drug Investig. 2019. https://doi.org/10.1007/s40261-019-00862-w.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Koren, G., Gilboa, D. & Katz, R. Expression of Concern to: Fetal Safety of Dydrogesterone Exposure in the First Trimester of Pregnancy. Clin Drug Investig 40, 681 (2020). https://doi.org/10.1007/s40261-019-00884-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40261-019-00884-4